目的 研究辛伐他汀联合二甲双胍治疗冠心病(CHD)合并2型糖尿病(T2DM)的临床效果。方法 选取2020年12月至2022年12月我院收治的116例CHD合并T2DM患者为研究对象，以随机数字表法将其分为对照组和观察组，各58例。两组均行常规治疗，对照组采用二甲双胍治疗，观察组采用辛伐他汀+二甲双胍治疗。比较两组的临床疗效、糖脂代谢指标、心功能指标、血清细胞因子水平及不良反应发生情况。结果 观察组的治疗总有效率高于对照组(P＜0。05)。治疗后，观察组的空腹血糖(FPG)、餐后2 h血糖(2 h PG)、总胆固醇(TC)、甘油三酯(TG)水平明显低于对照组(P＜0。05)。治疗后，观察组的心输出量(CO)、每搏输出量(SV)、心脏指数(CI)、舒张早期峰值流速/舒张晚期峰值流速(E/A)高于对照组(P＜0。05)。治疗后，观察组的肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、天冬酰胺内肽酶(LGMN)水平低于对照组，Meteorin-like蛋白(Metrnl)水平高于对照组(P＜0。05)。两组的不良反应总发生率比较，差异无统计学意义(P＞0。05)。结论 辛伐他汀联合二甲双胍治疗CHD合并T2DM的效果确切，可有效调控血糖、血脂，抑制炎症反应，促进心功能恢复。
Clinical effect of simvastatin combined with metformin in the treatment of coronary heart disease complicated with type 2 diabetes mellitus
Objective To study the clinical effect of simvastatin combined with metformin in the treatment of coronary heart disease(CHD)complicated with type 2 diabetes mellitus(T2DM).Methods A total of 116 patients with CHD complicated with T2DM admitted in our hospital from December 2020 to December 2022 were selected as the research objects and divided into control group and observation group by random number table method,with 58 cases in each group.Both groups received routine treatment,the control group was treated with metformin,and the observation group was treated with simvastatin+metformin.The clinical efficacy,glucose and lipid metabolism indexes,cardiac function indexes,serum cytokine levels and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group(P＜0.05).After treatment,the levels of fasting plasma glucose(FPG),2 hour postpradial glucose(2 h PG),total cholesterol(TC)and triglyceride(TG)in the observation group were significantly lower than those in the control group(P＜0.05).After treatment,the cardiac output(CO),stroke volume(SV),cardiac index(CI),maximum peak velocity of early diastolic/maximun peak velocity of late diastolic(E/A)in the observation group were higher than those in the control group(P＜0.05).After treatment,the levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and legumain(LGMN)in the observation group were lower than those in the control group,and the level of Meteorin-like protein(Metrnl)was higher than that in the control group(P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion Simvastatin combined with metformin is effective in the treatment of CHD with T2DM.It can effectively regulate blood glucose and blood lipids,inhibit inflammatory response,and promote the recovery of cardiac function.
万方数据
